Enrollment complete in Graybug’s phase 2b wet AMD treatment trial

The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release.
The multicenter, prospective, masked, randomized ALTISSIMO trial is comparing 1 mg and 2 mg dosing regimens of GB-102, a microparticle depot formulation of the anti-VEGF sunitinib malate, administered every 6 months and aflibercept administered every 2 months.
A limited interim safety analysis of the trial, which began in September 2019, supports the company’s plan to take the 1 mg dose forward, the release said. This

Full Story →